Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 1998

View Archived Issues

Antioxidant properties of DHLA suggest future therapeutic applications

PSSO: an alternative to hydrocortisone for the treatment of erythema

Cellomics receives funding for novel anticancer agent screens

Modafinil: a promising treatment for daytime somnolence in narcolepsy

Cortecs: half-year highlights

MK-677 shows efficacy in reversing diet-induced nitrogen wasting

High-dose topical capsaicin may reduce chronic debilitating nerve pain

Nicotine receptor activation may play a role in major depression

ZymeTx's ZStatFlu shows efficacy for detection of Hong Kong flu virus

Antiinflammatory agents with a good safety profile disclosed by Taisho

Cyclic sulfones synthesized at Pfizer inhibit MMPs and TNF production

U.S. patent will issue for D-Pharm's anticonvulsants

First regulatory filing for Vasomax in MED

Agents for VRE prepared at Lilly

FDA approves first ultrasound device for early diagnosis of osteoporosis

Inhibitors of CETP for hyperlipidemia/atherosclerosis in development at Bayer

Antiasthma effects of first-generation Primatized anti-CD4 MAb studied in patients

Merck & Co. reveals new prodrugs of fibrinogen receptor antagonists

Millennium discovers new antibiotic from fungal culture

Synergistic effects of montelukast and loratadine in allergic patients

Rotta describes potent and selective gastrin/CCK-B antagonists for CNS/gastrointestinal disorders

L-0066: a novel inhibitor of PDE IV and mediator release in vitro

FDA advisory committee recommends approval of capecitabine

Potential new indication for zafirlukast in the treatment of urticaria

Mochida describes new antiasthma agent with novel profile

Genetic basis for congenital kidney disease pinpointed by BioStratum scientists

Phase III trial of Procysteine i.v. suspended

Pyridorin looks promising for diabetic complications in preclinical models

Another Japanese merger in the making

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...